Abstract 2156
Background
The mobile application is a valuable tool in the transmission of information in terms of having easy access in our daily lives and hosting applications containing information specific to many diseases. After breast cancer surgery, the patients are generally preferred to have verbal expressions in their education. In this context, it is considered that mobile application is the right choice in order to provide the opportunity for the patients to manage their post-operative processes, to facilitate their access to the right information and to provide a positive contribution to their quality of life by providing consultancy services.
Methods
The text content of the mobile application has text, image, video and audio equipment as well as online support / consulting services. It is thought that the mobile application will have a separate interface for each problem, and text and animation content will be the only problem for each interface. Care was taken to ensure that the created interfaces were of different colors and the layout to be used for problem solving was similar for each interface. It was ensured that the patients were checked from the admin panel if they did not watch or watch the videos again. All these operations were entered by entering the user name and password and recorded by end-to-end encryption.
Results
Supporting self-care for a woman who has not yet achieved her responsibility to cope with all responsibilities will contribute to the maintenance of family unity. In the creation of a mobile application that can be reached continuously; It is aimed to support self-care, create a tool that can receive support without any social isolation, decrease individual dependence and increase self-esteem. Thus, the fact that the woman does not have to spend the post-operative period at home and can be used individually and at the desired time constitutes the other advantages of the mobile application.
Conclusions
If the patient with breast surgery has an equipment to support self-care in the post-operative home, it will be possible to decrease the rate of experiencing physiological, psychological and sociological problems. It will be possible for the patient who has no problems to decrease their applications to the hospital and to contribute to the economy of the country.
Clinical trial identification
Legal entity responsible for the study
Aydanur Aydin.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2600 - Atezolizumab (atezo) vs chemotherapy (chemo) in patients (pts) with platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): a long-term overall survival (OS) and safety update from the Phase III IMvigor211 study
Presenter: Michiel Van der Heijden
Session: Poster Display session 3
Resources:
Abstract
3598 - Three-Year Follow-Up From the Phase 3 KEYNOTE-045 Trial: Pembrolizumab (Pembro) Versus Investigator’s Choice (Paclitaxel, Docetaxel, or Vinflunine) in Recurrent, Advanced Urothelial Cancer (UC)
Presenter: Andrea Necchi
Session: Poster Display session 3
Resources:
Abstract
2382 - First Report of Efficacy and Safety From a Phase 2 Trial of Tislelizumab, an Anti-PD-1 Antibody, for the Treatment of PD-L1+ Locally Advanced or Metastatic Urothelial Carcinoma (UC) in Asian Patients
Presenter: Dingwei Ye
Session: Poster Display session 3
Resources:
Abstract
2388 - Quality of Life of Metastatic Urothelial Cancer (mUC) Patients Treated with Enfortumab Vedotin (EV) Following Platinum-Containing Chemotherapy and a Checkpoint Inhibitor (CPI): Data from EV-201 Cohort 1
Presenter: Bradley McGregor
Session: Poster Display session 3
Resources:
Abstract
3748 - Safety and efficacy of atezolizumab (atezo) in patients (pts) with autoimmune disease (AID): subgroup analysis of the SAUL study in locally advanced/metastatic urinary tract carcinoma
Presenter: Yohann Loriot
Session: Poster Display session 3
Resources:
Abstract
1126 - Validation of the VIO prognostic index in patients with metastatic urothelial carcinoma treated with immune-checkpoint inhibitors
Presenter: Rafael Morales Barrera
Session: Poster Display session 3
Resources:
Abstract
3693 - Pathologic outcomes after neoadjuvant chemotherapy for high-risk muscle invasive bladder cancer
Presenter: Justin Matulay
Session: Poster Display session 3
Resources:
Abstract
4840 - Analysis of response to prior therapies and therapies after treatment with erdafitinib in fibroblast growth factor receptor (FGFR)-positive patients (pts) with metastatic urothelial carcinoma (mUC)
Presenter: Arlene Siefker-Radtke
Session: Poster Display session 3
Resources:
Abstract
1221 - Clinical outcomes by sex with atezolizumab (atezo) monotherapy in patients (pts) with locally advanced/metastatic urothelial carcinoma (mUC)
Presenter: Jean Hoffman-censits
Session: Poster Display session 3
Resources:
Abstract
1715 - National Small Cell Bladder Cancer Audit: Results from 26 UK institutions
Presenter: Caroline Chau
Session: Poster Display session 3
Resources:
Abstract